A5046827092- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Kruppel-like factors research
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Multiple Myeloma Research and Treatments
- Hemoglobinopathies and Related Disorders
- Platelet Disorders and Treatments
- Chronic Lymphocytic Leukemia Research
- Cytokine Signaling Pathways and Interactions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Renal Diseases and Glomerulopathies
- Esophageal Cancer Research and Treatment
- Mast cells and histamine
- Lymphoma Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Protein Degradation and Inhibitors
- SARS-CoV-2 and COVID-19 Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Gastric Cancer Management and Outcomes
- Single-cell and spatial transcriptomics
- CAR-T cell therapy research
- Venous Thromboembolism Diagnosis and Management
- COVID-19 Clinical Research Studies
- Bone and Joint Diseases
Guy's and St Thomas' NHS Foundation Trust
2016-2025
St Thomas' Hospital
2014-2024
Guy's Hospital
2015-2024
King's College London
2019-2024
National Health Service
2013-2024
Oman Medical College
2024
Istanbul University
2023
Icahn School of Medicine at Mount Sinai
2023
Wake Forest University
2023
University of Toronto
2023
Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent selective Janus kinase (JAK) 1 2 inhibitor, as compared with best available therapy, in patients myelofibrosis.We assigned 219 intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera post-essential thrombocythemia to receive oral ruxolitinib therapy. The end point key secondary study were percentage at least 35% reduction spleen volume week 48 24, respectively,...
Somatic mutations in the Janus kinase 2 gene (JAK2) occur many myeloproliferative neoplasms, but molecular pathogenesis of neoplasms with nonmutated JAK2 is obscure, and diagnosis these remains a challenge.
The V617F mutation, which causes the substitution of phenylalanine for valine at position 617 Janus kinase (JAK) 2 gene (JAK2), is often present in patients with polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis. However, molecular basis these myeloproliferative disorders without mutation unclear.
We conducted a randomized comparison of hydroxyurea with anagrelide in the treatment essential thrombocythemia.
We present a review of critical concepts and produce recommendations on the management Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- second-line therapy, therapy for special issues. Key questions were selected according criterion clinical relevance. Statements produced using Delphi process, two consensus conferences involving panel 21 experts appointed by European LeukemiaNet (ELN) convened. Patients with polycythemia vera...
Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have clinical benefit in patients with polycythemia vera phase study. We conducted 3 open-label study evaluate the efficacy safety of ruxolitinib versus standard therapy who had an inadequate response or unacceptable side effects from hydroxyurea.We randomly assigned phlebotomy-dependent splenomegaly, 1:1 ratio, receive (110 patients) (112 patients). The primary end point both hematocrit control through week 32 at least 35%...
Cancers result from the accumulation of somatic mutations, and their properties are thought to reflect sum these mutations. However, little is known about effect order in which mutations acquired.We determined mutation patients with myeloproliferative neoplasms by genotyping hematopoietic colonies or means next-generation sequencing. Stem cells progenitor were isolated study on mature immature cells.The age at a patient presented neoplasm, acquisition JAK2 V617F homozygosity, balance...
Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied progression rates. The genomic characterization of patients myeloproliferative neoplasms offers the potential for personalized diagnosis, risk stratification, treatment.
Abstract Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies. COMFORT-II was randomized (2:1), open-label phase 3 study patients myelofibrosis; to BAT could crossover ruxolitinib upon protocol-defined disease progression or after primary end point, confounding long-term comparisons. At week 48, 28% (41/146) of achieved...
IMPORTANCE Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival.Fedratinib, JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF early-phase trials.OBJECTIVE To evaluate the efficacy safety of fedratinib therapy primary or secondary (post-polycythemia vera post-essential thrombocythemia) MF.DESIGN, SETTING, AND PARTICIPANTS...
Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development MPN-directed therapies. We aimed assess utility an abbreviated symptom score for most pertinent representative MPN subsequent serial use assessing response therapy.The Neoplasm Symptom Assessment Form total (MPN-SAF TSS) was calculated as mean 10 items from two previously validated scoring systems. Questions focus on fatigue,...
The number of red blood cells is normally tightly regulated by a classic homeostatic mechanism based on oxygen sensing in the kidney. Decreased delivery resulting from anemia induces production erythropoietin, which increases cell and hence delivery. Investigations erythropoietin regulation identified transcription factor hypoxia-inducible (HIF). HIF now recognized as being key regulator genes that function comprehensive range processes besides erythropoiesis, including energy metabolism...
Myelofibrosis is a hematologic malignancy characterized by splenomegaly and debilitating symptoms. Thrombocytopenia poor prognostic feature limits use of Janus kinase 1 (JAK1)/Janus 2 (JAK2) inhibitor ruxolitinib.To compare the efficacy safety JAK2 pacritinib with that best available therapy (BAT), including ruxolitinib, in patients myelofibrosis thrombocytopenia.For this phase 3 randomized international multicenter study-the PERSIST-2 study-of vs BAT, 311 platelet count 100 × 109/L or less...